SpyGlass Pharma, Inc. (SGP) - Net Assets
Based on the latest financial reports, SpyGlass Pharma, Inc. (SGP) has net assets worth $-98.84 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($115.87 Million) and total liabilities ($214.70 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SGP financial resilience to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-98.84 Million |
| % of Total Assets | -85.3% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SpyGlass Pharma, Inc. - Net Assets Trend (2023–2025)
This chart illustrates how SpyGlass Pharma, Inc.'s net assets have evolved over time, based on quarterly financial data. Also explore how large is SpyGlass Pharma, Inc.'s balance sheet for the complete picture of this company's asset base.
Annual Net Assets for SpyGlass Pharma, Inc. (2023–2025)
The table below shows the annual net assets of SpyGlass Pharma, Inc. from 2023 to 2025. For live valuation and market cap data, see SpyGlass Pharma, Inc. market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $-98.84 Million | -63.44% |
| 2024-12-31 | $-60.47 Million | -83.34% |
| 2023-12-31 | $-32.99 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SpyGlass Pharma, Inc.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6903241900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $5.89 Million | % |
| Total Equity | $-98.84 Million | 100.00% |
SpyGlass Pharma, Inc. Competitors by Market Cap
The table below lists competitors of SpyGlass Pharma, Inc. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Odfjell SE
OL:ODF
|
$696.79 Million |
|
Sido Muncul PT
JK:SIDO
|
$696.81 Million |
|
Ceepower Co Ltd
SHE:300062
|
$696.88 Million |
|
CEWE Stiftung & Co. KGaA
XETRA:CWC
|
$697.08 Million |
|
Independent Bank Corporation
NASDAQ:IBCP
|
$696.61 Million |
|
Linkage Software Co Ltd
SHG:688588
|
$696.56 Million |
|
Admie Holding S.A
AT:ADMIE
|
$696.51 Million |
|
Zhejiang Unifull Industrial Fibre Co Ltd
SHE:002427
|
$696.49 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SpyGlass Pharma, Inc.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -60,474,000 to -98,837,000, a change of -38,363,000.
- Net loss of 39,869,000 reduced equity.
- Share repurchases of 1,450,000 reduced equity.
- New share issuances of 127,336,000 increased equity.
- Other factors decreased equity by 124,380,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-39.87 Million | -40.34% |
| Share Repurchases | $1.45 Million | -1.47% |
| Share Issuances | $127.34 Million | +128.83% |
| Other Changes | $-124.38 Million | -125.84% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares SpyGlass Pharma, Inc.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2023-12-31 | $-1.03 | $20.84 | x |
| 2024-12-31 | $-1.90 | $20.84 | x |
| 2025-12-31 | $-3.10 | $20.84 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SpyGlass Pharma, Inc. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.02 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-23.12 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | $-29.99 Million |
Industry Comparison
This section compares SpyGlass Pharma, Inc.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $173,871,658
- Average return on equity (ROE) among peers: -26.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SpyGlass Pharma, Inc. (SGP) | $-98.84 Million | 0.00% | N/A | $696.61 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $98.85 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $1.59 Billion |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $309.44 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $181.29 Million |
| Abpro Holdings, Inc. (ABP) | $-75.73 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $189.45 Million | -60.80% | 0.14x | $795.12 Million |
| Arbutus Biopharma Corp (ABUS) | $200.23 Million | -28.52% | 0.14x | $854.72 Million |
| ABVC Biopharma Inc (ABVC) | $-5.75 Million | 0.00% | 0.00x | $27.18 Million |
| Abivax SA American Depositary Shares (ABVX) | $56.72 Million | -25.23% | 0.07x | $9.67 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $52.99 Million | -121.23% | 0.22x | $3.61 Billion |
About SpyGlass Pharma, Inc.
SpyGlass Pharma, Inc. operates as a biopharmaceutical company that provides treatment and drug delivery for patients living with chronic eye conditions. The company develops the Bimatoprost Drug Pad-IOL System (BIM-IOL System), including novel and proprietary drug pads attached to an intraocular lens (IOL), which is designed to be implanted during routine cataract surgery to reduce elevated intra… Read more